Insider Buying: Global Medical REIT (NYSE:XRN) CEO Acquires $169,700.00 in Stock

Posted by Brian Himes on May 15th, 2026

Global Medical REIT Inc. (NYSE:XRN – Get Free Report) CEO Mark Okey Decker, Jr. acquired 5,000 shares of the stock in a transaction dated Tuesday, May 12th. The shares were bought at an average cost of $33.94 per share, for a total transaction of $169,700.00. Following the completion of the transaction, the chief executive officer owned 59,774 shares in the company, valued at approximately $2,028,729.56. This represents a 9.13% increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the SEC, which is available through the SEC website.

Global Medical REIT Stock Up 0.7%

XRN stock opened at $34.56 on Friday. Global Medical REIT Inc. has a twelve month low of $29.05 and a twelve month high of $39.93. The company has a quick ratio of 0.61, a current ratio of 0.68 and a debt-to-equity ratio of 1.68. The stock has a market cap of $457.16 million, a P/E ratio of -31.13 and a beta of 1.11. The business’s 50-day moving average price is $34.98 and its 200-day moving average price is $34.47.

Global Medical REIT Announces Dividend

The business also recently disclosed a monthly dividend, which will be paid on Friday, September 18th. Stockholders of record on Thursday, August 20th will be given a dividend of $0.16 per share. This represents a c) dividend on an annualized basis and a dividend yield of 5.6%. The ex-dividend date of this dividend is Thursday, August 20th. Global Medical REIT’s payout ratio is presently -270.27%.

Analysts Set New Price Targets

XRN has been the topic of several research analyst reports. Weiss Ratings downgraded Global Medical REIT from a “hold (c-)” rating to a “sell (d+)” rating in a research report on Monday. Wall Street Zen downgraded Global Medical REIT from a “hold” rating to a “sell” rating in a research report on Saturday, May 9th. Finally, Compass Point restated a “neutral” rating and issued a $38.00 price objective (down from $50.00) on shares of Global Medical REIT in a research report on Thursday, May 7th. One equities research analyst has rated the stock with a Strong Buy rating, two have issued a Buy rating, two have issued a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, Global Medical REIT currently has a consensus rating of “Moderate Buy” and a consensus price target of $39.67.

Check Out Our Latest Analysis on XRN

Hedge Funds Weigh In On Global Medical REIT

Large investors have recently made changes to their positions in the business. Invesco Ltd. lifted its position in shares of Global Medical REIT by 4.2% in the fourth quarter. Invesco Ltd. now owns 310,432 shares of the company’s stock worth $10,474,000 after buying an additional 12,471 shares in the last quarter. Mackenzie Financial Corp purchased a new stake in shares of Global Medical REIT in the fourth quarter worth about $563,000. XTX Topco Ltd purchased a new stake in shares of Global Medical REIT in the fourth quarter worth about $515,000. Tudor Investment Corp ET AL purchased a new stake in shares of Global Medical REIT in the fourth quarter worth about $930,000. Finally, Clifford Capital Partners LLC lifted its position in shares of Global Medical REIT by 31.3% in the fourth quarter. Clifford Capital Partners LLC now owns 14,694 shares of the company’s stock worth $496,000 after buying an additional 3,504 shares in the last quarter. 57.52% of the stock is currently owned by hedge funds and other institutional investors.

About Global Medical REIT

(Get Free Report)

Global Medical REIT (NYSE: GMRE) is a real estate investment trust focused on owning and managing healthcare-related properties across the United States. The company acquires, develops and leases a diversified portfolio of medical office buildings, outpatient facilities, long-term care centers and other specialized healthcare real estate. By concentrating on essential healthcare assets, Global Medical REIT seeks to generate stable, long-term rental income under triple-net and modified gross lease structures.

Since its incorporation in 2016 and initial public offering in 2017, the company has pursued an acquisitive growth strategy targeting markets with strong demographic trends and limited supply of modern medical facilities.